Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy

Remo Panaccione, Silvio Danese, William J Sandborn, Christopher D O'Brien, Yiying Zhou, Hongyan Zhang, Omoniyi J Adedokun, Ilia Tikhonov, Stephan Targan, Maria T Abreu, Tadakazu Hisamatsu, Ellen J Scherl, Rupert W Leong, David S Rowbotham, Ramesh P Arasaradnam, Bruce E Sands, Colleen Marano

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy'. Together they form a unique fingerprint.

Medicine & Life Sciences